More on Optimer's (OPTR -8.2%) Q1 results: Dificid net sales of $16.8M versus $14.4M in Q1 2012....

|About: Optimer Pharmaceuticals, Inc. (OPTR)|By:, SA News Editor

More on Optimer's (OPTR -8.2%) Q1 results: Dificid net sales of $16.8M versus $14.4M in Q1 2012. The company sees a 5% increase in demand for the product but Needham's Alan Carr notes that consensus estimates were for Dificid sales of $20M and worries that the "concerning" sales trajectory (0% growth Q/Q) could reduce the premium any potential suitor might be willing to pay to acquire the company. (PR)